The Hormonal Control of Food Intake  by Coll, Anthony P. et al.
Leading Edge
ReviewThe Hormonal Control of Food Intake
Anthony P. Coll,1 I. Sadaf Farooqi,1 and Stephen O’Rahilly1,*
1Department of Clinical Biochemistry, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge CB2 2XY, 
United Kingdom
*Correspondence: so104@medschl.cam.ac.uk
DOI 10.1016/j.cell.2007.04.001
Numerous circulating peptides and steroids produced in the body influence appetite 
through their actions on the hypothalamus, the brain stem, and the autonomic nervous 
system. These hormones come from three major sites—fat cells, the gastrointestinal tract, 
and the pancreas. In this Review we provide a synthesis of recent evidence concerning the 
actions of these hormones on food intake.
Open access under CC BY license.Despite marked day-to-day fluctuations in food intake 
and physical activity, most healthy adult mammals main-
tain a steady body weight over many years. This indicates 
that cumulative energy intake is normally matched with 
great precision to energy expenditure. It has long been 
proposed that homeostatic regulators control energy 
balance. In the mid 20th century, Gordon Kennedy was 
the first to propose that circulating signals generated in 
proportion to body fat stores influenced food intake and 
energy expenditure in a coordinated manner to regulate 
body weight (Kennedy, 1953). A series of contempo-
raneous experiments in which regions of the hypotha-
lamus were physically ablated in rats showed that the 
hypothalamus was critical in this regulation (King, 2006). 
For example, damage to the ventromedial hypothala-
mus caused hyperphagia (eating in excess) and obesity 
whereas destruction of the lateral hypothalamus resulted 
in profound anorexia and weight loss. It was shown that 
circulating substances were capable of regulating food 
intake in parabiosis experiments (the surgical union of 
two animals allowing exchange of blood). Rats with 
lesions to the ventromedial hypothalamus parabiosed 
to normal animals remained hyperphagic and obese 
whereas the parabiosed partner ate less and lost weight. 
These experiments were the first to provide substantive 
evidence that a blood-borne satiety factor that was pro-
duced in obese animals required an intact hypothalamus 
for its activity.
Despite the robustness of these physiological obser-
vations it took more than 40 years before the molecules 
involved in such homeostatic control were identified. In 
the past decade the body of knowledge has grown rapidly 
and has resulted in a sea change in our understanding 
of the physiological processes that control food intake. 
We now know that a number of circulating peptides and 
steroids that are produced in the body can have a sub-
stantial influence on appetitive behavior through their 
actions on the hypothalamus, the brain stem, or afferent 
autonomic nerves. These hormones come from at least 
three sites: fat cells, the gastrointestinal tract, and the 
endocrine pancreas.Leptin
Progress toward identifying a circulating compound 
regulating satiation came from studying two naturally 
occurring obese mouse models, obese (ob/ob) and 
diabetic (db/db). Parabiosis experiments revealed ob/
ob mice were deficient in a circulating satiety factor, 
whereas db/db mice produced the factor in excess 
but lacked the ability to respond to it (see Friedman 
and Halaas, 1998). ob/ob mice were shown to har-
bor a loss-of-function mutation in the gene encod-
ing a secreted peptide, named leptin, that is pro-
duced largely, possibly exclusively, in adipose tissue 
(Zhang et al., 1994). Circulating concentrations of 
leptin appeared to mirror fat cell stores—increasing 
with overfeeding and decreasing with starvation. Lep-
tin administration to obese leptin-deficient animals 
reversed their hyperphagia, hypothermia, decreased 
locomotor activity, and all neuroendocrine and immu-
nological abnormalities (Friedman and Halaas, 1998). 
Humans genetically lacking leptin are also hyperphagic 
and severely obese and respond dramatically to leptin 
administration (Friedman and Halaas, 1998). Admin-
istration of leptin to fasted mice abrogates many of 
the neuroendocrine consequences of starvation, sug-
gesting that the normal biological role of leptin may be 
to aid the organism in monitoring transitions between 
adequately nourished and starved states (Friedman 
and Halaas, 1998).
The db/db phenotype is due to mutations in the 
receptor for leptin (OB-R), a class 1 cytokine receptor. 
A variety of homozygous and compound heterozygous 
loss-of-function mutations in the leptin receptor have 
also been found in severely obese humans (Farooqi et 
al., 2007). There are at least six isoforms of the leptin 
receptor (OB-Ra-f), primarily as a consequence of alter-
nate splicing. The main signaling isoform (and longest) 
is Ob-Rb. It is highly expressed in the hypothalamus and 
on immune cells and signals via the JAK-STAT pathway. 
Although the shorter forms of the receptor are more 
widely expressed than OB-Rb, their precise functions 
are unknown.Cell 129, April 20, 2007 ©2007 Elsevier Inc. 251
Figure 1. Control of Food Intake 
by the Hypothalamic Leptin-
 Melanocortin Pathway
The hypothalamus receives and integrates 
neural, metabolic, and hormonal signals to 
regulate energy homeostasis. In particular, 
the adipocyte-derived hormone leptin and 
the melanocortin pathway have a critical 
role in the control of food intake. 
AgRP, Agouti-related protein; Arc, arcuate 
nucleus; MC4R, melanocortin 4 receptor; 
POMC, pro-opiomelanocortin; PVN, par-
aventricular nucleus.Direct administration of leptin into the central nervous 
system (CNS) of ob/ob mice in doses that do not result 
in detectable levels in the periphery completely reverses 
the body weight and metabolic phenotype (Friedman 
and Halaas, 1998), emphasizing the importance of 
these central leptin receptors in most actions of leptin. 
Although leptin is effective at reducing food intake and 
body fat in leptin-deficient and normal rodents, it is rela-
tively ineffective in doing so in mice with diet-induced 
obesity. This is in accord with the observations that in 
human populations plasma leptin is positively correlated 
with fat mass; leptin administration to obese humans 
only has a modest and variable effect on body weight. 
These observations have led to the concept that “leptin 
resistance” may underlie the failure to regulate energy 
stores as seen in common forms of obesity. Although 
leptin has not become the panacea for obesity that was 
once hoped, it has undoubted actual and potential clini-
cal utility. It is life-saving in humans with congenital lep-
tin deficiency (Farooqi et al., 2002), has dramatic effects 
on the metabolic state of patients with lipodystrophy (a 
metabolic disorder characterized by selective loss of 
body fat and low leptin levels) (Oral et al., 2002), and 
shows promise as a therapeutic/diagnostic agent for 
weight-related reproductive disorders (Welt et al., 2004). 
Finally, up to 10% of obese people have relatively low 
leptin levels. Therapeutic trials of leptin supplementation 
in these individuals are overdue when, in combination 
with other agents, such therapy might be well suited to 
prevent weight regain after weight loss.
The critical importance of leptin in the control of 
energy homeostasis has been clearly established. 
However multiple intriguing questions remain. How and 
where does leptin act in the brain to regulate food intake 
and metabolism? What molecular mechanisms under-
lie leptin resistance? How is leptin secretion regulated? 
And what determines the large variation in leptin levels 
among individuals?
Leptin-Responsive Neurons in the Brain
The hypothalamus receives and integrates neural, meta-
bolic, and humoral signals from the periphery. In particular, 
contained within the arcuate nucleus of the hypothalamus 
are two populations of cells that are the best characterized 
leptin-responsive neurons in the brain (Cone, 2005). The 
first population of neurons express two potent appetite-252 Cell 129, April 20, 2007 ©2007 Elsevier Inc.stimulating (orexigenic) peptides, the melanocortin anat-
agonist Agouti-related peptide (AgRP) and Neuropeptide 
Y (NPY). The second population expresses the peptide 
cocaine and amphetamine-related transcript (CART) and 
the large precursor peptide pro-opiomelanocortin (POMC). 
Both sets of neurons project to second-order, melanocortin 
4 receptor (MC4R) expressing neurons within the hypotha-
lamus and elsewhere in the brain (Figure 1).
Leptin inhibits NPY/AgRP neurons, and fasting sig-
nificantly upregulates the expression of NPY and AgRP. 
Interestingly, germline deletion of NPY or AgRP has 
no major effect on body weight (see Cone, 2005; Flier, 
2004), although mice lacking AgRP do become mod-
estly lean late on in life due to an increase in energy 
expenditure (Wortley et al., 2005a). Recently four inde-
pendent groups, each using slightly different strategies, 
genetically ablated NPY/AgRP neurons postnatally (Flier, 
2006). Although the extent to which NPY/AgRP neurons 
were ablated in each study differed considerably, the 
message was clear—loss of NPY/AgRP neurons in adult 
life leads to profound, life-threatening hypophagia. Inter-
estingly, when these neurons are ablated in the newborn 
period the effects on body weight and food intake are 
much more modest, suggesting that network-based 
compensatory mechanisms can develop in neonates but 
do not readily occur in adults. It is as yet unclear whether 
the effects of ablation of these neurons on food intake 
are solely due to the loss of NPY and AgRP or whether 
the loss of other neurotransmitters is involved.
In contrast to NPY/AgRP neurons, POMC/CART neu-
rons are stimulated by leptin and fasting decreases POMC 
expression. Although CART deficiency does not appear 
to influence energy balance, there is clear evidence that 
POMC peptides play a critical role in feeding behavior 
with both POMC-deficient mice and humans develop-
ing hyperphagia and obesity (Coll et al., 2004). POMC 
undergoes extensive posttranslational modification to 
generate a range of smaller biologically active peptides, 
the melanocortins, which are agonists for melanocortin 
receptors. The ultimate pool of bioactive melanocortins 
released from POMC-expressing neurons is influenced 
by a number of factors including the activities of pro-
hormone convertases, carboxypeptidases, and both 
acetylases and deacetylases (Coll et al., 2004). Although 
α-melanocyte-stimulating hormone (α-MSH) has always 
been considered the predominant POMC-derived prod-
uct controlling energy balance, recent genetic evidence 
strongly implicates β-MSH in appetite regulation, at least 
in humans (Biebermann et al., 2006; Lee et al., 2006).
Leptin receptors are also found outside of the arcu-
ate nucleus, although the importance of leptin’s activity 
at these other sites has not been clear until recently. For 
instance, although the selective ablation of leptin recep-
tors in POMC neurons of the arcuate nucleus results in 
obesity (Balthasar et al., 2004), it is less pronounced than 
in mice that globally lack leptin receptor. Indeed, there 
are now clear data to show that leptin receptors on other 
neurons, such as those that express steroidogenic factor 
1 (SF1) in the ventromedial hypothalamus, are required 
for normal body weight (Dhillon et al., 2006). Mice lack-
ing leptin receptors on these neurons in the ventromedial 
hypothalamus become obese, despite having no discern-
ible increase in food intake. Interestingly, when placed 
on a high-fat diet, these mice appear unable to suppress 
food intake and adequately stimulate energy expenditure. 
Thus leptin receptors in SF-1 neurons of the ventromedial 
hypothalamus may play an important role in the adaptive 
changes critical for resisting diet-induced obesity.
However, there is still more to learn. Although mice 
with a combined deficiency of leptin receptors on both 
SF-1 and POMC neurons weighed more than those with 
loss of either alone, they were still less obese than mice 
that globally lack leptin receptors, indicating that there 
must be other sites important for leptin action. Two such 
sites may be the caudal brainstem and the ventral teg-
mental area in the midbrain. The caudal brainstem con-
tains both leptin-responsive, Ob-Rb-expressing neurons 
(Grill et al., 2002) and a population of POMC neurons, 
just like the arcuate nucleus. However, there appear to 
be some intriguing and important differences between 
the brainstem and the arcuate nucleus.
Although fasting induced a fall in POMC mRNA in both 
regions, in contrast to the arcuate, the reduction seen in 
the brainstem was not reversed by leptin administration. 
Furthermore, leptin did not cause STAT-3 phosphoryla-
tion or c-fos activation within brainstem POMC neurons, 
suggesting that leptin signaling via POMC-derived pep-
tides in the CNS occurs entirely via hypothalamic POMC 
neurons (Huo et al., 2006).
The ventral tegmental area contains dopaminergic 
neurons that have long been thought to play a role in 
the reward and motivational aspects of ingestive behav-
ior. Two recent studies now clearly indicate that by act-
ing upon these dopaminergic neurons, leptin influences 
food consumption in a hitherto unrecognized manner 
(Fulton et al., 2006; Hommel et al., 2006).
Further Downstream of Leptin
Melanocortin Receptors
Genetic deletion of MC4R in mice and humans results 
in severe hyperhagic obesity (Coll et al., 2004). MC4R 
mutations are responsible for up to 5% of cases of severe 
childhood obesity and between 0.5% and 2.5% of adult obesity (Hinney et al., 2006; Larsen et al., 2005). Esti-
mates of the frequency in the general population in the 
UK suggest a mutational frequency of 1/1000 (Alharbi et 
al., 2007), making MC4R deficiency one of the most com-
mon single-gene disorders. The phenotypic features of 
MC4R deficiency include hyperphagia, an increase in fat 
and lean mass, and an increase in bone mineral density 
(Farooqi et al., 2003). Of particular note is the finding 
that the severity of receptor dysfunction seen in in vitro 
assays can predict the amount of food ingested at a test 
meal by the subject harboring that particular mutation 
(Farooqi et al., 2003).
Until recently, it was uncertain as to whether each 
feature of the complex phenotype of MC4R deficiency 
could be ascribed to different regions of the brain. Did 
one site control food intake whereas another controlled 
energy expenditure? There are now clear data demon-
strating that there is indeed functional divergence of the 
melanocortin pathway (Balthasar et al., 2005). Using 
cre-lox technology, Balthasar and colleagues partially 
“rescued” MC4R-deficient mice by re-expressing Mc4r 
only in the paraventricular hypothalamus and the amy-
gdala. Although still heavier than control littermates, 
these mice were significantly lighter than mice globally 
lacking MC4Rs. This was entirely due to a normalization 
in food intake because the reduced energy intake typical 
of mice globally lacking Mc4r was unaffected by this tar-
geted re-expression. Thus MC4Rs in the paraventricular 
hypothalamus and/or amygdala appear to control food 
intake, but MC4Rs expressed elsewhere have a role in 
the control of energy expenditure.
The data that define the physiological function of 
MC3R in energy metabolism are not as dramatic as 
those for MC4R, although it is likely these two receptors 
serve nonredundant roles (Coll et al., 2004) Mice lacking 
Mc3r have a unique phenotype—despite an increased 
fat mass, their total body weight is similar to wild-type 
mice due to a reduction in lean mass. MC3R may influ-
ence feed efficiency (weight gain per kcal consumed) 
and the partitioning of fuel stores into fat.
BDNF/TrkB
A number of recent studies have given insights into the 
mediators and signaling mechanisms that lie beyond the 
melanocortin receptors. In particular, a growing body of 
evidence implicates brain-derived neurotrophic factor 
(BDNF) as a player in energy homeostasis. BDNF is a 
regulator of brain development and plasticity and exerts 
its effects through the tyrosine kinase receptor TrkB. 
Both BDNF and its receptor TrkB are widely expressed 
in the brain. Mice lacking either one copy of the Bdnf 
gene or with a tissue-specific conditional deletion of 
Bdnf in the postnatal brain develop hyperphagia and 
obesity (Rios et al., 2001). Administration of BDNF can 
ameliorate the hyperphagia and metabolic disturbance 
in db/db mice (Nakagawa et al., 2000). An exciting study 
reported that MC4R and BDNF/TRk-B-mediated signal-
ing may be coupled in the regulation of energy balance 
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expressed in the ventromedial nucleus, with expression 
regulated by nutritional status and by MC4R signaling. 
The authors also showed that mice with a hypomorphic 
mutation in trkb (resulting in expression levels 25% of 
normal) closely resembled mice lacking Mc4r in that 
they developed hyperphagia and obesity, increased 
body length, and excessive weight gain on a high-fat 
diet. Further, central infusion of BDNF into mice with 
deficient MC4R signaling suppressed the hyperphagia 
and excessive weight gain observed on high-fat diets. In 
humans, genetic disruption of the neurotrophin receptor 
TrkB (Yeo et al., 2004) and in its ligand BDNF (Gray et al., 
2006) cause severe hyperphagia and obesity, develop-
mental delay, impaired short-term memory, and unusu-
ally hyperactive behavior.
Melanin-Concentrating Hormone
Melanin-concentrating hormone (MCH) is an orexigenic 
(appetite-stimulating) peptide produced by neurons in 
the lateral hypothalamus. Robust data from rodent mod-
els demonstrate that MCH has a critical role in energy 
balance (Flier, 2004). Mice lacking MCH are hypophagic 
and lean whereas transgenic overexpression of MCH 
in the lateral hypothalamus leads to obesity and insulin 
resistance. The key role of this neuropeptide in integrat-
ing the downstream effects of leptin is demonstrated by 
the fact that MCH expression is increased in hypotha-
lami of ob/ob mice, with a dramatic reduction in body fat 
seen in ob/ob mice also lacking MCH.
Of note, loss of the receptor believed to be respon-
sible for the action of MCH (MCH1R) results in hyper-
phagia, but mice lacking Mch1r mice remain lean as a 
consequence of hyperactivity and altered metabolism. 
More recently, targeted ablation of MCH neurons has 
been demonstrated to cause hypophagia, increased 
energy expenditure, and late-onset leanness (Alon and 
Friedman, 2006).
Orexins
Orexins were originally identified as peptides produced 
selectively in the lateral hypothalamus (Sakurai et al., 
1998). Central administration of orexin appeared to 
increase food intake in mice leading to the initial view 
that the principal function of orexins was the control of 
food intake. However, subsequent studies suggest that 
orexins play a more important role in the maintenance of 
alertness with genetic or acquired deficiency of orexin 
signaling resulting in narcolepsy (Saper et al., 2005). A 
possible link with the leptin and the adipostatic pathways 
remains in that leptin administration decreases orexin 
expression whereas fasting increases orexin mRNA lev-
els (Yamanaka et al., 2003).
Others
The hypothalamic transcription factor Single-minded 
1 (Sim1) is expressed in a number of regions known to 
be involved in energy homeostasis, including the par-
aventricular nucleus and the lateral hypothalamus. 
Haploinsufficiency of Sim1 is associated with hyper-
phagic obesity and increased linear growth (Kublaoui 
et al., 2006; Michaud et al., 2001), closely resembling 254 Cell 129, April 20, 2007 ©2007 Elsevier Inc.the phenotype of agouti yellow (Ay) and Mc4r null mice, 
two classic models of disrupted hypothalamic melano-
cortin signaling. These similarities may be because MC4 
receptors involved in the regulation of food intake sig-
nal through Sim1 and/or its transcriptional targets. Sim1 
heterozygous mice remain hyperphagic despite elevated 
hypothalamic Pomc expression and have an impaired 
anorectic (appetite-suppressing) response to melano-
cortins, suggesting that Sim1-expressing neurons in the 
paraventricular nucleus regulate feeding in response to 
melanocortin signaling (Kublaoui et al., 2006).
Serotonin (5-hydroxytrypamine, 5-HT) derived drugs 
have long been known to have clinical utility in the induc-
tion of weight loss, but the neural pathways through 
which central serotonergic systems regulate food intake 
have remained elusive. It now appears that serotonin-
induced hypophagia requires downstream activation of 
MC4R, with the central melanocortin system a key site 
of action of 5-HT. Not only does 5-HT inhibit NPY/AgRP 
neurons but it also activates POMC neurons, leading 
to an increase in activity at MC4R in target sites and a 
reduction in food intake (Heisler et al., 2006).
Developmental Effects of Leptin
Recent data have elegantly described how leptin can 
potently influence neuronal growth and development. By 
studying the electrophysiological activity in neurons from 
ob/ob mice, it was shown that leptin deficiency markedly 
changes synaptic inputs to arcuate neurons, increasing 
excitatory inputs on NPY/AgRP neurons but decreasing 
excitatory inputs to POMC neurons (Pinto et al., 2004). 
Critically, within hours of administration to ob/ob mice, 
leptin was able to reverse these effects, thereby demon-
strating it to be a crucial regulator of synaptic plasticity. 
Leptin appears also to be a neurotrophic growth factor 
during hypothalamic development (Bouret et al., 2004) 
with leptin deficiency severely reducing the density of 
innervations from the arcuate nucleus to the paraven-
tricular nucleus, lateral hypothalamus, and dorsomedial 
nucleus—all regions implicated in the control of energy 
balance. Leptin replacement in adult life appears inef-
fective in reversing this axonal pattern, but, in sharp con-
trast, replacement in early postnatal life (a time when a 
surge in plasma leptin levels in rodents has long been 
recognized) can restore the density of innervations to 
second-order neurons to that of wild-type mice. This 
raises interesting questions as to whether there is a criti-
cal period of leptin-dependent hypothalamic develop-
ment in the early neonatal period that may have major 
ramifications for energy balance later in life. If true, this 
“altered wiring” could, in part, explain the profound, 
early-onset obesity seen in leptin-deficient children.
However, the fact that leptin replacement therapy in 
leptin-deficient adults with established morbid obes-
ity results in profound weight loss (Licinio et al., 2004) 
means that even if a hypothalamic signaling system 
developed entirely in the absence of leptin, the ability to 
respond in a physiological manner to leptin is retained. 
Further, studies using the neurocytokine ciliary neuro-
trophic factor (CNTF) suggest that a previously unap-
preciated degree of neuroproliferative potential contin-
ues into adult life (Kokoeva et al., 2005). CNTF has the 
remarkable ability to induce weight loss that persists 
after the cessation of treatment. CNTF induces cell pro-
liferation in feeding centers within the hypothalamus, 
with many of the newborn cells behaving like neuronal 
cells known to be critical in energy balance.
Mechanisms of Leptin Resistance
In the majority of cases of obesity, despite both an intact 
leptin receptor and high circulating levels, leptin fails to 
bring about weight loss. This diminished response to 
the anorexigenic effects of leptin is referred to as “lep-
tin resistance.” What may be the potential mechanisms 
underlying this resistance?
A failure of circulating leptin to reach its target recep-
tor within the brain appears to be one mechanism at 
work in rodents with diet-induced obesity, a classic 
model of leptin resistance. In contrast, leptin resist-
ance in aged rats may result from decreased expres-
sion of the leptin receptor within hypothalamic neurons 
(see Bates and Myers, 2003; Flier, 2004). However, a 
hypothesis that has received recent attention is that 
leptin resistance may be due to an attenuation of the 
intracellular leptin signaling cascade. Suppressor of 
cytokine signaling-3 (Socs-3) is an intracellular protein 
that negatively regulates the action of various cytokine 
receptors. It is now recognized to act to limit leptin sig-
naling and therefore is a potential mediator of leptin 
resistance. Indeed, although complete lack of Socs-3 
is embryonic lethal, mice with only one functional copy 
of Socs-3 or those with neuronal deletion of Socs-3 
are lean and leptin sensitive (Howard et al., 2004; Kie-
vit et al., 2006; Mori et al., 2004). Kievit et al. further 
highlighted the key role Socs-3 plays in leptin signal-
ing by demonstrating that selective deletion of Socs-3 
from POMC-expressing neurons alone also results in 
enhanced leptin sensitivity and resistance to weight 
gain on a high-fat diet. Finally, recent data that dem-
onstrate that mice with a neuron-specific lack of the 
tyrosine phosphatase PTP1B are rendered hypersensi-
tive to leptin point to this molecule having an important 
role in the development of leptin resistance (Bence et 
al., 2006).
Leptin resistance remains enigmatic. In part this is 
because of the inaccessibility of the relevant leptin-
resistant neurons in humans and the difficulty of isolat-
ing unique neuronal subpopulations in a mass of other 
neurons presumably not involved in leptin action. In 
contrast to the history of insulin resistance when the 
characterization of the insulin receptor, combined with 
accessibility of insulin’s target tissues, rapidly permit-
ted the classification of insulin-resistant states as “pre-
receptor,” “receptor-related,” or “post-receptor,” it is still 
extremely difficult to confidently classify leptin-resistant 
humans or rodents in this manner.What Regulates Leptin Secretion?
The adipocyte is not a classical endocrine cell and lep-
tin is not stored in typical endocrine secretory granules. 
The amount of leptin produced by an adipocyte appears 
to be regulated at the transcriptional level but also at 
the levels of translation, storage, turnover, and secre-
tion (Lee and Fried, 2006). Leptin levels do show some 
diurnal variation, but this appears to be entrained by 
meal times in rodents. Insulin and glucocorticoids posi-
tively regulate leptin production whereas agents that 
increase cAMP levels in the adipocyte, such as β adren-
ergic agonists, suppress leptin production (Ricci et al., 
2005). The marked sexual dimorphism in plasma levels 
(much higher in females than males) is, at least in part, 
explained by a suppressive effect of androgens on leptin 
production. The precise mechanisms whereby increased 
fat stores are signaled to the adipose tissue mass to pro-
duce more leptin remains mysterious, and progress has 
been impeded by very low levels of leptin made in the 
otherwise very useful adipocyte cell lines in which much 
adipocyte cell biology has been established.
Other Signals from Adipocytes
Adiponectin
Adiponectin is an adipocyte-derived hormone that 
has been proposed to play an important role in energy 
homeostasis (Trujillo and Scherer, 2005). It has strong 
sequence homology with C1q and type VIII and X col-
lagen and its C-terminal globular domain has a tertiary 
structure that resembles TNFα. In sharp contrast to lep-
tin, plasma adiponectin levels are negatively correlated 
with body fat, decreasing with obesity and increasing 
in response to weight loss. Adiponectin also circulates 
in plasma at a much higher concentration than leptin 
(µg/ml versus ng/ml, respectively). Data from knockout 
mouse models suggest that adiponectin is protective 
against the development of insulin resistance, glucose 
intolerance, and dyslipidemia (Nawrocki et al., 2006). 
However, the evidence that adiponectin has a role in 
controlling food intake is less convincing. Although 
ectopic overproduction of adiponectin can reduce food 
intake in high-fat-fed rats and offset the development of 
diet-induced obesity (Shklyaev et al., 2003), food intake 
in adiponectin knockout mice is no different from that 
seen in wild-type littermates (Maeda et al., 2002).
Interleukins
Interleukin 6 (IL-6) is a cytokine that has diverse roles 
in immunoregulation and the inflammatory response. It 
is also secreted from adipose tissue, particularly omen-
tal fat (the fat surrounding the bowels), independently of 
any acute inflammatory condition. Like leptin, IL-6 levels 
correlate with total body fat. Mice lacking IL-6 are not 
hyperphagic but become modestly obese in adult life as 
a result of disruption in energy expenditure (Wallenius et 
al., 2002). However, a combined deficiency of IL-6 and 
interleukin 1 (IL-1) does cause hyperphagia and a more 
marked obesity (Chida et al., 2006). In addition, loss of 
the fat-derived cytokine interleukin 18 (IL-18) leads to Cell 129, April 20, 2007 ©2007 Elsevier Inc. 255
hyperphagia and obesity. Interestingly, the administra-
tion of recombinant IL-18 does not alleviate hyperphagia 
in IL-18 knockout mice if injected intravenously but does 
if it is injected into the cerebral ventricles (Netea et al., 
2006). This suggests that IL-18 might have a role in the 
regulation of food intake by the CNS.
The Gastrointestinal Tract
Cholecystokinin
Cholecystokinin (CCK) is a gut peptide that has long 
been established to act as a postprandial satiety signal 
(Chaudhri et al., 2006). It is released into the circulation 
from enteroendocrine cells of the duodenum and jeju-
num in response to fatty acids (Figure 2). CCK acts at 
receptors on peripheral vagal afferent terminals, which 
transmit signal to appetite centers, such as the nucleus of 
the solitary tract, contained within the brainstem. Periph-
eral administration of CCK also activates mouse POMC 
neurons in the nucleus of the solitary tracts with signal-
ing via MC4Rs in this region appearing to be crucial in 
bringing about the satiety effects of CCK. This peptide is 
ineffective in reducing food intake in mice lacking MC4R 
and in mice in which brainstem melanocortin receptors 
are blocked pharmacologically (Fan et al., 2004). Thus in 
Figure 2. Hormones from the Gut and Endocrine Organs 
Affect Food Intake
Hormonal signals derived from the gut and classical endocrine or-
gans, such as the pancreas, thyroid, and adrenal glands act in synergy 
to effect changes in feeding behavior.
CCK, cholecystokinin; OXM, oxyntomodulin; GLP-1, glucagon-like 
peptide 1; PYY3–36, peptide YY3–36.256 Cell 129, April 20, 2007 ©2007 Elsevier Inc.addition to integrating long-term adipostatic signals like 
leptin, the melanocortin system may also be important in 
integrating short-term gut-derived satiety signals.
PYY3–36
Peptide YY (PYY) is a 36 amino acid peptide secreted 
from the endocrine L cells of the gut. Circulating PYY 
levels are low in the fasting state and rapidly increase 
postprandially when two forms, PYY1–36 and PYY3–36, 
are released into the circulation. Both peptides have 
local effects on gut motility and both have the ability 
to increase food intake if administered directly into the 
cerebrospinal fluid of animals. In contrast, peripherally 
administered PYY3–36 can reduce food intake (Chaudhri 
et al., 2006) . Like leptin, the appetite-suppressing effects 
of PYY3–36 were initially thought to be mediated indirectly 
through the central melanocortin system. However, this 
appears not to be the case as a disrupted melancortin-
ergic system still permits the full anorexigenic effects of 
PYY3–36 (Coll et al., 2004). Some groups have reported 
difficulty in reliably reproducing the anorexigenic effects 
of PYY3–36 (Tschop et al., 2004), a phenomenon that may 
reflect the influence of environmental stimuli on the abil-
ity of the animals to respond. It has been suggested that 
the inhibition of food intake by PYY3–36 is dependent, at 
least in part, on the induction of an aversive response 
(Halatchev and Cone, 2005). However, recent data from 
a new Pyy null mouse model have supplied evidence 
that PYY may indeed have a physiological role in eating 
behavior, in particular mediating the satiating effects of 
dietary protein (Batterham et al., 2006).
In humans, PYY3–36 levels are elevated in many disease 
states that are characterized by weight loss. Overweight 
subjects have been reported to have a relative deficiency 
of postprandial PYY3–36 release associated with reduced 
satiety (le Roux et al., 2006b) and bariatric surgery results 
in an exaggerated postprandial PYY3–36 surge, potentially 
explaining the effectiveness of such surgery in main-
taining a prolonged reduction in postoperative weight 
(le Roux et al., 2006a). Whether or not PYY3–36 is a true 
endogenous physiological regulator of food intake, long-
term trials of PYY3–36 as an antiobesity agent are ongoing, 
and the results are awaited with great interest.
Ghrelin
Ghrelin was discovered as an endogenous ligand for 
the growth hormone secretagogue receptor (GHSR). 
The octanoylated 28 amino acid peptide is produced 
and secreted by cells within the oxyntic glands of the 
stomach. Ghrelin mRNA expression and peptide secre-
tion are increased by weight loss, fasting, and insulin-
induced hypoglycaemia. Peripheral administration of 
ghrelin stimulates food intake and decreases fat utiliza-
tion. Thus, ghrelin has been proposed to be an enteric 
signal involved in energy homeostasis, being unique in 
that it stimulates appetite rather than acting as a satiety 
signal (Williams and Cummings, 2005).
There is considerable evidence to indicate that the 
classical arcuate-based pathways are central to ghre-
lin’s effects on food intake (Williams and Cummings, 
2005). Given this, the first reports of mice with targeted 
deletions of ghrelin exhibiting no changes in feeding 
behavior or body composition were somewhat surpris-
ing (Sun et al., 2003; Wortley et al., 2004). GHSR knock-
out animals were also only modestly lean (Sun et al., 
2004). However, more detailed studies of the metabolic 
phenotype of mice lacking ghrelin (Wortley et al., 2005b) 
or GHSR (Zigman et al., 2005) report that both are resist-
ant to diet-induced obesity when fed a high-fat diet, eat-
ing less and preferentially utilizing more stored fat as an 
energy substrate than wild-type mice. These data lend 
support to the notion that ghrelin-responsive pathways 
are an important component of coordinated body-weight 
control. Very recently there has been a report that rats 
vaccinated with ghrelin can produce neutralizing anti-
bodies to the hormone and that this is associated with 
decreased rates of weight gain (Zorrilla et al., 2006).
In addition to being produced in the stomach, ghre-
lin may also be produced within the brain. A new set of 
ghrelin-positive neurons within the hypothalamus, lying 
between the dorsal, ventral, paraventricular, and arcuate 
nuclei, were identified by immunohistochemistry (Cowley 
et al., 2003). The functional relevance of brain-derived 
ghrelin remains to be determined. However, there is now 
evidence that the central actions of ghrelin are of physi-
ological relevance in the control of adipocyte metabo-
lism (Theander-Carrillo et al., 2006). Chronic infusion of 
ghrelin into the CNS not only increases lipogenesis and 
inhibits lipid oxidation in white adipose tissue but also 
decreases expression of UCP 1 and 3 in brown fat, in 
keeping with a reduction in energy expenditure. Thus, 
central ghrelin appears to partition nutrients toward fat 
storage by favoring an increase in glucose and triglyc-
eride uptake, increasing lipogenesis, and inhibiting lipid 
oxidation in white adipocytes. This fits in well with the 
phenotype of ghrelin-deficient mice described earlier, 
where under conditions of abundant dietary fat, the 
impaired adipocyte metabolism becomes functionally 
relevant and leads to a decreased susceptibility to diet-
induced obesity. Further, this may also suggest an alter-
native role for the well-known pre-meal surge in ghrelin. 
Rather than being a signal of meal initiation, this change 
in circulating ghrelin may trigger in the CNS processes 
that prepare the body to receive and appropriately proc-
ess in-coming nutrients.
Obestatin
Ghrelin is derived from the posttranslational processing 
of the 117 amino acid prohormone preproghrelin. A recent 
study by Zhang et al. has suggested that subtle but dis-
tinctly different processing of this precursor generates a 
peptide that directly opposes the effect of ghrelin on food 
intake (Zhang et al., 2005). Using a bioinformatics search 
to look for typical enzymatic cleavage sites in other large 
precursors of peptide hormones, Zhang et al. identified a 
23 amino acid region of pre-proghrelin that is flanked by 
potential convertase cleavage sites. Further characteriza-
tion of the predicted peptide revealed it to be a circulating 
peptide, which, like ghrelin, was also detectable within the stomach wall of rats. In vivo studies with a synthetic ver-
sion of the peptide demonstrated that it suppressed food 
intake, inhibited jejeunal contraction, and decreased body 
weight, all in sharp contrast to the orexigenic effects of 
ghrelin. On the basis of these suppressive effects on food 
intake the peptide was duly named “obestatin”—derived 
from the Latin “obedere” —to devour. By screening a range 
of mammalian orphan receptors, Zhang et al. showed that 
obestatin appeared to be working via GPR39, a G pro-
tein-coupled receptor that is expressed in the stomach, 
in the intestines, and within the hypothalamus. Thus, it 
appeared that two antagonistic hormones were derived 
from the same gene, with differential posttranslational 
modification resulting in peptide products with apparently 
opposing effects. Certainly, this neat processing trick 
might be an attractive hypothesis to explain how models 
of ghrelin deficiency outlined earlier appear to have such 
a bland phenotype. In knocking out the orexigen ghre-
lin, mutant mice were also rendered deficient in the ano-
rexigen obestatin. However, the true biological function of 
obestatin remains uncertain. For example, the circulating 
levels of obestatin appear to be far lower than those of 
ghrelin, and in sharp contrast to ghrelin, there appears to 
be no change in circulating obestatin upon fasting or re-
feeding in rodents. Although these anomalies may be due 
to as yet unappreciated subtlety in the peptide-process-
ing systems, the excitement of the initial report must be 
tempered by more recent data that have failed to show 
any effect of obestatin on food intake in rodents (Holst et 
al., 2007; Nogueiras et al., 2007).
Glucagon-like Peptide-1
Glucagon-like peptide-1 (GLP-1) is a peptide product of 
the proglucagon gene, released from the L cells of the 
small intestine in response to food ingestion (Drucker, 
2006). GLP-1 is a potent inducer of glucose-dependent 
insulin release. This has lead to the development of GLP-
1 agonists that have clinical utility in the treatment of 
type 2 diabetes mellitus (Drucker, 2006). GLP-1 can also 
influence food intake with the GLP-1 analog exenatide, 
capable of lowering both blood glucose and body weight 
in obese type 2 diabetic subjects. The effects on body 
weight may be as a result of induction of satiety via inhi-
bition of gastric emptying, but there is also evidence 
that GLP-1 can influence feeding behavior by acting at 
the nucleus of the solitary tract in the brainstem and the 
paraventricular nucleus of the hypothalamus (Chaudhri 
et al., 2006).
Oxyntomodulin
Like GLP-1, oxyntomodulin (OXM) is also produced 
from the proglucagon gene and released from the small 
intestine in response to a meal. Physiologically, it acts 
to reduce gastric motility and secretion. Although a 
unique receptor for OXM has yet to be identified, data 
from rodent and human studies suggest that systemic 
administration of OXM can reduce both food intake and 
body weight with some of these effects brought about 
by a suppression of the orexigenic hormone ghrelin 
(Chaudhri et al., 2006).Cell 129, April 20, 2007 ©2007 Elsevier Inc. 257
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Insulin
Insulin receptors are widely distributed in the brain with 
the highest concentrations found in the olfactory bulb, 
hippocampus, cerebral cortex, and the arcuate nucleus 
within the hypothalamus. The existence of neural circuits 
that appeared to respond to insulin and regulate food 
intake and adipose mass was reported many years before 
leptin was discovered (Schwartz et al., 1992). Despite 
this, neuron-specific loss of insulin receptors only has 
subtle effects on food intake and body weight (Bruning 
et al., 2000). Female (but not male) mice with disruption 
of the insulin receptor gene in the CNS become hyper-
phagic and overweight (10%–15% heavier than control), 
but this may be confounded by a reproductive endocrine 
phenotype.
The importance of a more localized population of 
insulin receptors, in particular those within the hypotha-
lamus, has been further delineated. Obici et al. (2002) 
were able to significantly reduce hypothalamic insulin 
signaling by directly injecting into the third ventricle an 
antisense oligonucleotide designed to blunt the expres-
sion of insulin receptor in adjacent nuclei. This resulted 
in a rapid and significant hyperphagia, associated with 
an increase in the expression of both NPY and AgRP.
However, the role of insulin signaling at POMC 
neurons is not entirely clear. Choudhury et al. (2005) 
generated mice that lacked insulin receptor substrate 
2 (IRS2) in POMC neurons. IRS2 is a major media-
tor of the metabolic effects of insulin. In contrast to 
the effects of leptin receptor loss from POMC neu-
rons, mice lacking IRS2 from these neurons had no 
discernible phenotype, being neither hyperphagic nor 
obese, suggesting that insulin signaling in POMC neu-
rons does not play a major role in energy homeos-
tasis. Moreover, further complexity comes from data 
demonstrating that, in direct contrast to leptin, insulin 
actually hyperpolarizes POMC neurons and decreases 
the neuronal firing rate, indicating that the anorexi-
genic effects of insulin are unlikely to be mediated via 
POMC neurons (Plum et al., 2006).
After many decades of experiment and debate it is still 
difficult to place insulin’s role in the normal physiology 
of energy homeostasis. Insulin undoubtedly has a major 
and nonredundant role in the control of the disposition 
of nutrients in the periphery. Although insulin clearly 
has appetite-suppressive effects when administered to 
the CNS, the physiological significance of such actions 
remains uncertain.
Pancreatic Polypeptide
Pancreatic polypeptide (PP) is released from cells found 
at the periphery of pancreatic islets, again in propor-
tion to the amount of calories ingested with the effect 
of inhibiting gastric emptying. Whether PP has an addi-
tional physiological role in the control of food intake 
remains uncertain although infusions of PP mimicking 
the postprandial rise can suppress food intake in man 
(Chaudhri et al., 2006).258 Cell 129, April 20, 2007 ©2007 Elsevier Inc.Other Sites
Circulating levels of glucocorticoids derived from the 
adrenal gland are able to profoundly affect appetite (Dall-
man et al., 2004). Anorexia is a feature of the cortisol defi-
ciency seen in primary adrenal failure, whereas an excess 
of glucocorticoids can cause hyperphagia. Glucocorti-
coids also have a significant impact upon the melanocor-
tin system. Adrenalectomy reverses the obese phenotype 
in leptin-deficient ob/ob mice and by normalizing both the 
increase in AgRP expression and the decrease in POMC 
expression found in ob/ob mice restores hypothalamic 
melanocortin tone (Makimura et al., 2000). In addition, the 
orexigenic effect of the melanocortin antagonist AgRP is 
absent in adrenalectomized rats but restored with sup-
plementation of glucocorticoids (Drazen et al., 2003).
Steroid hormones derived from the gonads have also 
been implicated in the modulation of eating behav-
ior. Exciting recent data have shown that estradiol can 
reduce body weight by increasing excitatory synapses 
upon POMC soma. This increase in POMC neuronal 
activity results in both a reduction in energy intake and 
an increase in energy expenditure (Gao et al., 2007).
Thyroid hormones can influence feeding behavior, 
as tri-iodothyronine (T3), acting in the CNS, is able to 
increase food intake (Kong et al., 2004). However, this 
must be tempered by the fact that T3 induces a marked 
increase in basal metabolic rate, and thus any increase 
in food intake may be a compensatory response to this 
increase in energy expenditure.
Hepatocyte-derived C-reactive protein (CRP) has been 
correlated with adiposity and levels of plasma leptin. Chen 
et al. (2006) have reported that CRP binds leptin, that this 
interaction attenuates leptin action in vivo, and that leptin 
stimulates CRP production from hepatocytes. This sug-
gests a possible vicious cycle in which the stimulation of 
CRP production by leptin leads to the production of greater 
quantities of a leptin antagonist, thereby being a potential 
mechanism contributing to leptin resistance seen in obese 
subjects. However, the relationship between CRP and lep-
tin remains uncertain. For example, we have recently found 
that when leptin-naïve children with congenital leptin defi-
ciency are treated with leptin there is no change in circu-
lating CRP concentrations (Farooqi and O’Rahilly, 2007), 
and we have been unable to find any antagonism of leptin 
actions in mice co-treated with leptin and a 6-fold molar 
excess of highly purified CRP (Hutchinson et al., 2007).
Summary
The genetic evidence for a critical role of leptin and its 
downstream anorexigenic pathways in the control of 
food intake is extremely strong and highly suggestive 
of a system with little redundancy. The severe and con-
tinued hyperphagia seen in rodents and humans when 
the leptin signaling system is disrupted, which persists 
in the face of extreme expansion of the adipose tissue 
mass, suggests that other adipocyte-derived signals 
play at most a subsidiary role in adipostatic control of 
food intake.
In contrast, the evidence for one particular gut-derived 
peptide having such a singular role in appetitive control 
is weaker, suggestive of a system in which there is a high 
degree of redundancy. However, this does not exclude 
a physiological role for such peptides. Instead, it sug-
gests the presence of an integrated system in which adi-
pocyte-derived signals provide tonic, long-term infor-
mation to the brain about the state of nutrient stores, 
whereas a variety of signals triggered by ingestive sta-
tus have important roles in influencing meal initiation 
and termination. Future experiments directed toward the 
simultaneous ablation of multiple putatively anorectic 
gut- and pancreas-derived peptides should help clarify 
the impact of the gut-brain axis in meal termination and 
initiation.
An improved understanding of the normal physiology 
of energy homeostasis and the endocrine control of food 
intake will have profound implications for the develop-
ment of effective therapeutic and preventive strategies 
for human obesity. Contrary to popular misconception, 
obesity is not a new disease that has suddenly appeared 
as a result of a toxic environment. Human populations 
have always consisted of individuals with a broad range 
of adiposity, with those at the top end of the distribu-
tion suffering adverse health consequences. Recent 
changes in the availability and cost of palatable energy-
dense food and the reduction in physical activity during 
work and recreation have undoubtedly contributed to 
an overall upward shift in the adiposity of entire popu-
lations. However, even in communities with substantial 
obesity there is still a high proportion of subjects who 
are lean. The heritability of adiposity is very high, and 
the most parsimonious explanation is that genetically 
based variation in the homeostatic pathways control-
ling energy balance determines the interindividual differ-
ences in susceptibility or resistance to an environment 
that fosters obesity. Such a model does not exclude the 
fact that body weight can be altered by voluntary efforts 
of human will but adds the important rider that the 
ease with which this can be achieved differs markedly 
between people and suggests that those differences 
are likely to be based on the variable intensity of inher-
ent biological drives, not “moral fiber.” This conceptual 
approach to the undoubted health problem of obesity 
should encourage biomedical scientists to, as Friedman 
has put it, “make war on obesity, not the obese” (Fried-
man, 2003).
REFEREnCEs
Alharbi, K.K., Spanakis, E., Tan, K., Smith, M.J., Aldahmesh, M.A., 
O’Dell, S.D., Sayer, A.A., Lawlor, D.A., Ebrahim, S., Smith, G.D., et 
al. (2007). Prevalence and functionality of paucimorphic and private 
MC4R mutations in a large, unselected European British population, 
scanned by meltMADGE. Hum Mutat 28, 294–302. 
Alon, T., and Friedman, J.M. (2006). Late-onset leanness in mice with 
targeted ablation of melanin concentrating hormone neurons. J. Neu-
rosci. 26, 389–397.
Balthasar, N., Dalgaard, L.T., Lee, C.E., Yu, J., Funahashi, H., Williams, T., Ferreira, M., Tang, V., McGovern, R.A., Kenny, C.D., et al. (2005). 
Divergence of melanocortin pathways in the control of food intake and 
energy expenditure. Cell 123, 493–505.
Balthasar, N., Coppari, R., McMinn, J., Liu, S.M., Lee, C.E., Tang, V., 
Kenny, C.D., McGovern, R.A., Chua, SC., Elmquist, J.K., and Lowell, 
B.B. (2004). Leptin receptor signaling in POMC neurons is required for 
normal body weight homeostasis. Neuron 42, 983–991.
Bates, S.H., and Myers, M.G., Jr. (2003). The role of leptin receptor 
signaling in feeding and neuroendocrine function. Trends Endocrinol. 
Metab. 14, 447–452.
Batterham, R.L., Heffron, H., Kapoor, S., Chivers, J.E., Chandarana, 
K., Herzog, H., Le Roux, C.W., Thomas, E.L., Bell, J.D., and Withers, 
D.J. (2006). Critical role for peptide YY in protein-mediated satiation 
and body-weight regulation. Cell Metab. 4, 223–233.
Bence, K.K., Delibegovic, M., Xue, B., Gorgun, C.Z., Hotamisligil, 
G.S., Neel, B.G., and Kahn, B.B. (2006). Neuronal PTP1B regulates 
body weight, adiposity and leptin action. Nat. Med. 12, 917–924.
Biebermann, H., Castaneda, T.R., van Landeghem, F., von Deimling, 
A., Escher, F., Brabant, G., Hebebrand, J., Hinney, A., Tschop, M.H., 
Gruters, A., and Krude, H. (2006). A role for beta-melanocyte-stimu-
lating hormone in human body-weight regulation. Cell Metab. 3, 
141–146.
Bouret, S.G., Draper, S.J., and Simerly, R.B. (2004). Trophic action of 
leptin on hypothalamic neurons that regulate feeding. Science 304, 
108–110.
Bruning, J.C., Gautam, D., Burks, D.J., Gillette, J., Schubert, M., Or-
ban, P.C., Klein, R., Krone, W., Muller-Wieland, D., and Kahn, C.R. 
(2000). Role of brain insulin receptor in control of body weight and 
reproduction. Science 289, 2122–2125.
Chaudhri, O., Small, C., and Bloom, S. (2006). Gastrointestinal hor-
mones regulating appetite. Philos. Trans. R. Soc. Lond. B Biol. Sci. 
361, 1187–1209.
Chen, K., Li, F., Li, J., Cai, H., Strom, S., Bisello, A., Kelley, D.E., Fried-
man-Einat, M., Skibinski, G.A., McCrory, M.A., et al. (2006). Induction 
of leptin resistance through direct interaction of C-reactive protein 
with leptin. Nat. Med. 12, 425–432.
Chida, D., Osaka, T., Hashimoto, O., and Iwakura, Y. (2006). Com-
bined interleukin-6 and interleukin-1 deficiency causes obesity in 
young mice. Diabetes 55, 971–977.
Choudhury, A.I., Heffron, H., Smith, M.A., Al-Qassab, H., Xu, A.W., 
Selman, C., Simmgen, M., Clements, M., Claret, M., Maccoll, G., et 
al. (2005). The role of insulin receptor substrate 2 in hypothalamic and 
beta cell function. J. Clin. Invest. 115, 940–950.
Coll, A.P., Farooqi, I.S., Challis, B.G., Yeo, G.S., and O’Rahilly, S. 
(2004). Proopiomelanocortin and energy balance: insights from hu-
man and murine genetics. J. Clin. Endocrinol. Metab. 89, 2557–2562.
Cone, R.D. (2005). Anatomy and regulation of the central melanocortin 
system. Nat. Neurosci. 8, 571–578.
Cowley, M.A., Smith, R.G., Diano, S., Tschop, M., Pronchuk, N., Grove, 
K.L., Strasburger, C.J., Bidlingmaier, M., Esterman, M., Heiman, M.L., 
et al. (2003). The distribution and mechanism of action of ghrelin in 
the CNS demonstrates a novel hypothalamic circuit regulating energy 
homeostasis. Neuron 37, 649–661.
Dallman, M.F., la Fleur, S.E., Pecoraro, N.C., Gomez, F., Houshyar, 
H., and Akana, S.F. (2004). Minireview: glucocorticoids–food intake, 
abdominal obesity, and wealthy nations in 2004. Endocrinology 145, 
2633–2638.
Dhillon, H., Zigman, J.M., Ye, C., Lee, C.E., McGovern, R.A., Tang, 
V., Kenny, C.D., Christiansen, L.M., White, R.D., Edelstein, E.A., et al. 
(2006). Leptin directly activates SF1 neurons in the VMH, and this ac-
tion by leptin is required for normal body-weight homeostasis. Neuron 
49, 191–203.Cell 129, April 20, 2007 ©2007 Elsevier Inc. 259
Drazen, D.L., Wortman, M.D., Schwartz, M.W., Clegg, D.J., van Dijk, 
G., Woods, S.C., and Seeley, R.J. (2003). Adrenalectomy alters the 
sensitivity of the central nervous system melanocortin system. Dia-
betes 52, 2928–2934.
Drucker, D.J. (2006). The biology of incretin hormones. Cell Metab. 
3, 153–165.
Fan, W., Ellacott, K.L., Halatchev, I.G., Takahashi, K., Yu, P., and 
Cone, R.D. (2004). Cholecystokinin-mediated suppression of feed-
ing involves the brainstem melanocortin system. Nat. Neurosci. 7, 
335–336.
Farooqi, I.S., and O’Rahilly, S. (2007). Is leptin an important physi-
ological regulator of CRP? Nat. Med. 13, 16–17.
Farooqi, I.S., Matarese, G., Lord, G.M., Keogh, J.M., Lawrence, E., 
Agwu, C., Sanna, V., Jebb, S.A., Perna, F., Fontana, S., et al. (2002). 
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and 
neuroendocrine/metabolic dysfunction of human congenital leptin de-
ficiency. J. Clin. Invest. 110, 1093–1103.
Farooqi, I.S., Keogh, J.M., Yeo, G.S., Lank, E.J., Cheetham, T., and 
O’Rahilly, S. (2003). Clinical spectrum of obesity and mutations in the 
melanocortin 4 receptor gene. N. Engl. J. Med. 348, 1085–1095.
Farooqi, I.S., Wangensteen, T., Collins, S., Kimber, W., Matarese, 
G., Keogh, J.M., Lank, E., Bottomley, B., Lopez-Fernandez, J., Fer-
raz-Amaro, I., et al. (2007). Clinical and molecular genetic spectrum 
of congenital deficiency of the leptin receptor. N. Engl. J. Med. 356, 
237–247.
Flier, J.S. (2004). Obesity wars: molecular progress confronts an ex-
panding epidemic. Cell 116, 337–350.
Flier, J.S. (2006). AgRP in energy balance: Will the real AgRP please 
stand up? Cell Metab. 3, 83–85.
Friedman, J.M. (2003). A war on obesity, not the obese. Science 299, 
856–858.
Friedman, J.M., and Halaas, J.L. (1998). Leptin and the regulation of 
body weight in mammals. Nature 395, 763–770.
Fulton, S., Pissios, P., Manchon, R.P., Stiles, L., Frank, L., Pothos, 
E.N., Maratos-Flier, E., and Flier, J.S. (2006). Leptin regulation of the 
mesoaccumbens dopamine pathway. Neuron 51, 811–822.
Gao, Q., Mezei, G., Nie, Y., Rao, Y., Choi, C.S., Bechmann, I., Leranth, 
C., Toran-Allerand, D., Priest, C.A., Roberts, J.L., et al. (2007). Anorec-
tic estrogen mimics leptin’s effect on the rewiring of melanocortin cells 
and Stat3 signaling in obese animals. Nat. Med. 13, 89–94.
Gray, J., Yeo, G.S., Cox, J.J., Morton, J., Adlam, A.L., Keogh, J.M., 
Yanovski, J.A., El Gharbawy, A., Han, J.C., Tung, Y.C., et al. (2006). 
Hyperphagia, severe obesity, impaired cognitive function, and hyper-
activity associated with functional loss of one copy of the brain-de-
rived neurotrophic factor (BDNF) gene. Diabetes 55, 3366–3371.
Grill, H.J., Schwartz, M.W., Kaplan, J.M., Foxhall, J.S., Breininger, J., 
and Baskin, D.G. (2002). Evidence that the caudal brainstem is a tar-
get for the inhibitory effect of leptin on food intake. Endocrinology 
143, 239–246.
Halatchev, I.G., and Cone, R.D. (2005). Peripheral administration of 
PYY(3-36) produces conditioned taste aversion in mice. Cell Metab. 
1, 159–168.
Heisler, L.K., Jobst, E.E., Sutton, G.M., Zhou, L., Borok, E., Thornton-
Jones, Z., Liu, H.Y., Zigman, J.M., Balthasar, N., Kishi, T., et al. (2006). 
Serotonin reciprocally regulates melanocortin neurons to modulate 
food intake. Neuron 51, 239–249.
Hinney, A., Bettecken, T., Tarnow, P., Brumm, H., Reichwald, K., Li-
chtner, P., Scherag, A., Nguyen, T.T., Schlumberger, P., Rief, W., et 
al. (2006). Prevalence, spectrum, and functional characterization of 
melanocortin-4 receptor gene mutations in a representative popula-
tion-based sample and obese adults from Germany. J. Clin. Endocri-260 Cell 129, April 20, 2007 ©2007 Elsevier Inc.nol. Metab. 91, 1761–1769.
Holst, B., Egerod, K.L., Schild, E., Vickers, S.P., Cheetham, S., Ger-
lach, L.O., Storjohann, L., Stidsen, C.E., Jones, R., Beck-Sickinger, 
A.G., and Schwartz, T.W. (2007). GPR39 signaling is stimulated by 
zinc ions but not by obestatin. Endocrinology 148, 13–20.
Hommel, J.D., Trinko, R., Sears, R.M., Georgescu, D., Liu, Z.W., Gao, 
X.B., Thurmon, J.J., Marinelli, M., and DiLeone, R.J. (2006). Leptin 
receptor signaling in midbrain dopamine neurons regulates feeding. 
Neuron 51, 801–810.
Howard, J.K., Cave, B.J., Oksanen, L.J., Tzameli, I., Bjorbaek, C., and 
Flier, J.S. (2004). Enhanced leptin sensitivity and attenuation of diet-
induced obesity in mice with haploinsufficiency of Socs3. Nat. Med. 
10, 734–738.
Huo, L., Grill, H.J., and Bjorbaek, C. (2006). Divergent regulation of 
proopiomelanocortin neurons by leptin in the nucleus of the solitary 
tract and in the arcuate hypothalamic nucleus. Diabetes 55, 567–
573.
Hutchinson, W.L., Coll, A.P., Gallimore, J.R., Tennent, G.A., and 
Pepys, M.B. (2007). Is leptin an important physiological regulator of 
CRP? Nat. Med. 13, 17–18.
Kennedy, G.C. (1953). The role of depot fat in the hypothalamic con-
trol of food intake in the rat. Proc. R. Soc. Lond. B. Biol. Sci. 140, 
578–596.
Kievit, P., Howard, J.K., Badman, M.K., Balthasar, N., Coppari, R., Mori, 
H., Lee, C.E., Elmquist, J.K., Yoshimura, A., and Flier, J.S. (2006). En-
hanced leptin sensitivity and improved glucose homeostasis in mice 
lacking suppressor of cytokine signaling-3 in POMC-expressing cells. 
Cell Metab. 4, 123–132.
King, B.M. (2006). The rise, fall, and resurrection of the ventromedial 
hypothalamus in the regulation of feeding behavior and body weight. 
Physiol. Behav. 87, 221–244.
Kokoeva, M.V., Yin, H., and Flier, J.S. (2005). Neurogenesis in the hy-
pothalamus of adult mice: potential role in energy balance. Science 
310, 679–683.
Kong, W.M., Martin, N.M., Smith, K.L., Gardiner, J.V., Connoley, I.P., 
Stephens, D.A., Dhillo, W.S., Ghatei, M.A., Small, C.J., and Bloom, 
S.R. (2004). Triiodothyronine stimulates food intake via the hypotha-
lamic ventromedial nucleus independent of changes in energy expen-
diture. Endocrinology 145, 5252–5258.
Kublaoui, B.M., Holder, J.L., Jr., Gemelli, T., and Zinn, A.R. (2006). 
Sim1 haploinsufficiency impairs melanocortin-mediated anorexia and 
activation of paraventricular nucleus neurons. Mol. Endocrinol. 20, 
2483–2492.
Larsen, L.H., Echwald, S.M., Sorensen, T.I., Andersen, T., Wulff, B.S., 
and Pedersen, O. (2005). Prevalence of mutations and functional anal-
yses of melanocortin 4 receptor variants identified among 750 men 
with juvenile-onset obesity. J. Clin. Endocrinol. Metab. 90, 219–224.
le Roux, C.W., Aylwin, S.J., Batterham, R.L., Borg, C.M., Coyle, F., 
Prasad, V., Shurey, S., Ghatei, M.A., Patel, A.G., and Bloom, S.R. 
(2006a). Gut hormone profiles following bariatric surgery favor an ano-
rectic state, facilitate weight loss, and improve metabolic parameters. 
Ann. Surg. 243, 108–114.
le Roux, C.W., Batterham, R.L., Aylwin, S.J., Patterson, M., Borg, 
C.M., Wynne, K.J., Kent, A., Vincent, R.P., Gardiner, J., Ghatei, M.A., 
and Bloom, S.R. (2006b). Attenuated peptide YY release in obese 
subjects is associated with reduced satiety. Endocrinology 147, 3–8.
Lee, M.J., and Fried, S.K. (2006). Multilevel regulation of leptin stor-
age, turnover, and secretion by feeding and insulin in rat adipose tis-
sue. J. Lipid Res. 47, 1984–1993.
Lee, Y.S., Challis, B.G., Thompson, D.A., Yeo, G.S., Keogh, J.M., Ma-
donna, M.E., Wraight, V., Sims, M., Vatin, V., Meyre, D., et al. (2006). A 
POMC variant implicates beta-melanocyte-stimulating hormone in the 
control of human energy balance. Cell Metab. 3, 135–140.
Licinio, J., Caglayan, S., Ozata, M., Yildiz, B.O., de Miranda, P.B., 
O’Kirwan, F., Whitby, R., Liang, L., Cohen, P., Bhasin, S., et al. (2004). 
Phenotypic effects of leptin replacement on morbid obesity, diabetes 
mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc. 
Natl. Acad. Sci. USA 101, 4531–4536.
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., 
Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et 
al. (2002). Diet-induced insulin resistance in mice lacking adiponectin/
ACRP30. Nat. Med. 8, 731–737.
Makimura, H., Mizuno, T.M., Roberts, J., Silverstein, J., Beasley, J., 
and Mobbs, C.V. (2000). Adrenalectomy reverses obese phenotype 
and restores hypothalamic melanocortin tone in leptin-deficient ob/ob 
mice. Diabetes 49, 1917–1923.
Michaud, J.L., Boucher, F., Melnyk, A., Gauthier, F., Goshu, E., Levy, 
E., Mitchell, G.A., Himms-Hagen, J., and Fan, C.M. (2001). Sim1 
haploinsufficiency causes hyperphagia, obesity and reduction of the 
paraventricular nucleus of the hypothalamus. Hum. Mol. Genet. 10, 
1465–1473.
Mori, H., Hanada, R., Hanada, T., Aki, D., Mashima, R., Nishinakamu-
ra, H., Torisu, T., Chien, K.R., Yasukawa, H., and Yoshimura, A. (2004). 
Socs3 deficiency in the brain elevates leptin sensitivity and confers 
resistance to diet-induced obesity. Nat. Med. 10, 739–743.
Nakagawa, T., Tsuchida, A., Itakura, Y., Nonomura, T., Ono, M., Hirota, 
F., Inoue, T., Nakayama, C., Taiji, M., and Noguchi, H. (2000). Brain-de-
rived neurotrophic factor regulates glucose metabolism by modulat-
ing energy balance in diabetic mice. Diabetes 49, 436–444.
Nawrocki, A.R., Rajala, M.W., Tomas, E., Pajvani, U.B., Saha, A.K., 
Trumbauer, M.E., Pang, Z., Chen, A.S., Ruderman, N.B., Chen, H., et 
al. (2006). Mice lacking adiponectin show decreased hepatic insulin 
sensitivity and reduced responsiveness to peroxisome proliferator-ac-
tivated receptor gamma agonists. J. Biol. Chem. 281, 2654–2660.
Netea, M.G., Joosten, L.A., Lewis, E., Jensen, D.R., Voshol, P.J., Kull-
berg, B.J., Tack, C.J., van Krieken, H., Kim, S.H., Stalenhoef, A.F., et 
al. (2006). Deficiency of interleukin-18 in mice leads to hyperphagia, 
obesity and insulin resistance. Nat. Med. 12, 650–656.
Nogueiras, R., Pfluger, P., Tovar, S., Arnold, M., Mitchell, S., Morris, 
A., Perez-Tilve, D., Vazquez, M.J., Wiedmer, P., Castaneda, T.R., et al. 
(2007). Effects of obestatin on energy balance and growth hormone 
secretion in rodents. Endocrinology 148, 21–26.
Obici, S., Feng, Z., Karkanias, G., Baskin, D.G., and Rossetti, L. (2002). 
Decreasing hypothalamic insulin receptors causes hyperphagia and 
insulin resistance in rats. Nat. Neurosci. 5, 566–572.
Oral, E.A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., 
Wagner, A.J., DePaoli, A.M., Reitman, M.L., Taylor, S.I., et al. (2002). 
Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 
570–578.
Pinto, S., Roseberry, A.G., Liu, H., Diano, S., Shanabrough, M., Cai, 
X., Friedman, J.M., and Horvath, T.L. (2004). Rapid rewiring of arcuate 
nucleus feeding circuits by leptin. Science 304, 110–115.
Plum, L., Ma, X., Hampel, B., Balthasar, N., Coppari, R., Munzberg, 
H., Shanabrough, M., Burdakov, D., Rother, E., Janoschek, R., et 
al. (2006). Enhanced PIP3 signaling in POMC neurons causes KATP 
channel activation and leads to diet-sensitive obesity. J. Clin. Invest. 
116, 1886–1901.
Ricci, M.R., Lee, M.J., Russell, C.D., Wang, Y., Sullivan, S., Schneider, 
S.H., Brolin, R.E., and Fried, S.K. (2005). Isoproterenol decreases 
leptin release from rat and human adipose tissue through posttran-
scriptional mechanisms. Am. J. Physiol. Endocrinol. Metab. 288, 
E798–E804.
Rios, M., Fan, G., Fekete, C., Kelly, J., Bates, B., Kuehn, R., Lechan, 
R.M., and Jaenisch, R. (2001). Conditional deletion of brain-derived 
neurotrophic factor in the postnatal brain leads to obesity and hyper-activity. Mol. Endocrinol. 15, 1748–1757.
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tana-
ka, H., Williams, S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., 
et al. (1998). Orexins and orexin receptors: a family of hypothalamic 
neuropeptides and G protein-coupled receptors that regulate feeding 
behavior. Cell 92, 573–585.
Saper, C.B., Scammell, T.E., and Lu, J. (2005). Hypothalamic regula-
tion of sleep and circadian rhythms. Nature 437, 1257–1263.
Schwartz, M.W., Figlewicz, D.P., Baskin, D.G., Woods, S.C., and Porte, 
D., Jr. (1992). Insulin in the brain: a hormonal regulator of energy bal-
ance. Endocr. Rev. 13, 387–414.
Shklyaev, S., Aslanidi, G., Tennant, M., Prima, V., Kohlbrenner, E., 
Kroutov, V., Campbell-Thompson, M., Crawford, J., Shek, E.W., Scar-
pace, P.J., and Zolotukhin, S. (2003). Sustained peripheral expression 
of transgene adiponectin offsets the development of diet-induced 
obesity in rats. Proc. Natl. Acad. Sci. USA 100, 14217–14222.
Sun, Y., Ahmed, S., and Smith, R.G. (2003). Deletion of ghrelin impairs 
neither growth nor appetite. Mol. Cell. Biol. 23, 7973–7981.
Sun, Y., Wang, P., Zheng, H., and Smith, R.G. (2004). Ghrelin stimula-
tion of growth hormone release and appetite is mediated through the 
growth hormone secretagogue receptor. Proc. Natl. Acad. Sci. USA 
101, 4679–4684.
Theander-Carrillo, C., Wiedmer, P., Cettour-Rose, P., Nogueiras, R., 
Perez-Tilve, D., Pfluger, P., Castaneda, T.R., Muzzin, P., Schurmann, 
A., Szanto, I., et al. (2006). Ghrelin action in the brain controls adipo-
cyte metabolism. J. Clin. Invest. 116, 1983–1993.
Trujillo, M.E., and Scherer, P.E. (2005). Adiponectin–journey from an 
adipocyte secretory protein to biomarker of the metabolic syndrome. 
J. Intern. Med. 257, 167–175.
Tschop, M., Castaneda, T.R., Joost, H.G., Thone-Reineke, C., Ort-
mann, S., Klaus, S., Hagan, M.M., Chandler, P.C., Oswald, K.D., 
Benoit, S.C., et al. (2004). Physiology: does gut hormone PYY3-36 
decrease food intake in rodents? Nature 430, 1 p following 165; dis-
cussion 2 p following 165. 
Wallenius, V., Wallenius, K., Ahren, B., Rudling, M., Carlsten, H., Dick-
son, S.L., Ohlsson, C., and Jansson, J.O. (2002). Interleukin-6-defi-
cient mice develop mature-onset obesity. Nat. Med. 8, 75–79.
Welt, C.K., Chan, J.L., Bullen, J., Murphy, R., Smith, P., DePaoli, A.M., 
Karalis, A., and Mantzoros, C.S. (2004). Recombinant human leptin 
in women with hypothalamic amenorrhea. N. Engl. J. Med. 351, 987–
997.
Williams, D.L., and Cummings, D.E. (2005). Regulation of ghrelin in 
physiologic and pathophysiologic states. J. Nutr. 135, 1320–1325.
Wortley, K.E., Anderson, K.D., Garcia, K., Murray, J.D., Malinova, L., 
Liu, R., Moncrieffe, M., Thabet, K., Cox, H.J., Yancopoulos, G.D., et 
al. (2004). Genetic deletion of ghrelin does not decrease food intake 
but influences metabolic fuel preference. Proc. Natl. Acad. Sci. USA 
101, 8227–8232.
Wortley, K.E., Anderson, K.D., Yasenchak, J., Murphy, A., Valenzuela, 
D., Diano, S., Yancopoulos, G.D., Wiegand, S.J., and Sleeman, M.W. 
(2005a). Agouti-related protein-deficient mice display an age-related 
lean phenotype. Cell Metab. 2, 421–427.
Wortley, K.E., del Rincon, J.P., Murray, J.D., Garcia, K., Iida, K., Thorn-
er, M.O., and Sleeman, M.W. (2005b). Absence of ghrelin protects 
against early-onset obesity. J. Clin. Invest. 115, 3573–3578.
Xu, B., Goulding, E.H., Zang, K., Cepoi, D., Cone, R.D., Jones, K.R., 
Tecott, L.H., and Reichardt, L.F. (2003). Brain-derived neurotrophic 
factor regulates energy balance downstream of melanocortin-4 recep-
tor. Nat. Neurosci. 6, 736–742.
Yamanaka, A., Beuckmann, C.T., Willie, J.T., Hara, J., Tsujino, N., Mie-
da, M., Tominaga, M., Yagami, K., Sugiyama, F., Goto, K., et al. (2003). Cell 129, April 20, 2007 ©2007 Elsevier Inc. 261
Hypothalamic orexin neurons regulate arousal according to energy 
balance in mice. Neuron 38, 701–713.
Yeo, G.S., Connie Hung, C.C., Rochford, J., Keogh, J., Gray, J., Si-
varamakrishnan, S., O’Rahilly, S., and Farooqi, I.S. (2004). A de novo 
mutation affecting human TrkB associated with severe obesity and 
developmental delay. Nat. Neurosci. 7, 1187–1189.
Zhang, J.V., Ren, P.G., Avsian-Kretchmer, O., Luo, C.W., Rauch, R., 
Klein, C., and Hsueh, A.J. (2005). Obestatin, a peptide encoded by 
the ghrelin gene, opposes ghrelin’s effects on food intake. Science 
310, 996–999.262 Cell 129, April 20, 2007 ©2007 Elsevier Inc.Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Fried-
man, J.M. (1994). Positional cloning of the mouse obese gene and its 
human homologue. Nature 372, 425–432.
Zigman, J.M., Nakano, Y., Coppari, R., Balthasar, N., Marcus, J.N., 
Lee, C.E., Jones, J.E., Deysher, A.E., Waxman, A.R., White, R.D., et al. 
(2005). Mice lacking ghrelin receptors resist the development of diet-
induced obesity. J. Clin. Invest. 115, 3564–3572.
Zorrilla, E.P., Iwasaki, S., Moss, J.A., Chang, J., Otsuji, J., Inoue, K., 
Meijler, M.M., and Janda, K.D. (2006). From the cover: Vaccination 
against weight gain. Proc. Natl. Acad. Sci. USA 103, 13226–13231.
